Sharp is set to expand the capacity of its Allentown and Conshohocken facilities in Pennsylvania, US, with an investment of $21m.
The Allentown expansion includes a co-investment from the company’s clients and marks the third phase of development of its biotechnology centre of excellence.
As part of the expansion, the facility will feature new equipment installations such as vial labellers and a cold sterilisation system.
Sharp Packaging US president Kevin Orfan said: “We are seeing increased demand for our packaging capabilities from clients across the biotech industry, with the injectables sector growing significantly in recent years.
“We are making these capacity expansions on behalf of our clients and through our parent company UDG Healthcare. Sharp has invested continuously to keep pace with demand for our services. This expansion is intended to support that demand into the future.”
Established in April 2016, the Allentown Campus started as an injectables centre of excellence. It also has an additional undeveloped space of approximately 21,500ft².
The company recently expanded the facility with a double pre-filled syringe (PFS), autoinjector and pen assembly. It also increased its cold storage capacity.
Sharp announced plans to increase its global cold storage and syringe assembly capacity with an investment of $11m in a bid to meet market demand.
The company used the investment to install Groninger labelling machines at its facility in Allentown, US. The investment doubled the Sharp’s syringe assembly capacity facility.